Abstract
Our rapidly expanding understanding of the molecular pathogenesis of a variety of cancers is providing new molecular targets for drug development; specifically, immunomodulatory and antiangiogenic agents are poised to become essential in novel cancer therapeutics. Rationale for the development of such therapies rest in the observation that these immune and angiogenic targets (e.g. TNF-α , VEGF, IL-6, IL-2 and IFN-γ ) are at the core of cancer growth and progression, and are aberrant and deregulated in many human malignancies. Successful immunomodulation and inhibition of aberrant angiogenesis pathways are essential for malignant tumor cells. Herein we present an overview of immune modulation and angiogenesis in cancer. We will also review preclinical and clinical development, pharmacology and clinical trials of lenalidomide (Revlimid®, formerly CC-5013; Celgene Corporation), and agent that alters both pathways.
Keywords: CC-5013, immunomodulator, angiogenesis inhibitor, lenalidomide, thalidomide
Current Cancer Therapy Reviews
Title: Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation
Volume: 2 Issue: 3
Author(s): Tanyifor M. Tohny, Jurgen Venitz, Alex Sparreboom and William D. Figg
Affiliation:
Keywords: CC-5013, immunomodulator, angiogenesis inhibitor, lenalidomide, thalidomide
Abstract: Our rapidly expanding understanding of the molecular pathogenesis of a variety of cancers is providing new molecular targets for drug development; specifically, immunomodulatory and antiangiogenic agents are poised to become essential in novel cancer therapeutics. Rationale for the development of such therapies rest in the observation that these immune and angiogenic targets (e.g. TNF-α , VEGF, IL-6, IL-2 and IFN-γ ) are at the core of cancer growth and progression, and are aberrant and deregulated in many human malignancies. Successful immunomodulation and inhibition of aberrant angiogenesis pathways are essential for malignant tumor cells. Herein we present an overview of immune modulation and angiogenesis in cancer. We will also review preclinical and clinical development, pharmacology and clinical trials of lenalidomide (Revlimid®, formerly CC-5013; Celgene Corporation), and agent that alters both pathways.
Export Options
About this article
Cite this article as:
Tohny M. Tanyifor, Venitz Jurgen, Sparreboom Alex and Figg D. William, Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation, Current Cancer Therapy Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339406777934690
DOI https://dx.doi.org/10.2174/157339406777934690 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer
Current Cancer Therapy Reviews Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Regulation and Function of Antimicrobial Peptides in Immunity and Diseases of the Lung
Protein & Peptide Letters Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry C-Jun Terminal Kinases Play an Important Role in Regulating Embryonic Survival and Eye Development in Vertebrates
Current Molecular Medicine The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Current Advances in Antibody Immobilization on Different Surfaces and Beads
Current Proteomics Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets Synthesis, Antitumor Activity and Molecular Docking Studies on Seven Novel Thiazacridine Derivatives
Combinatorial Chemistry & High Throughput Screening The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab
Recent Patents on Biotechnology Aryl Butenes Active against K562 Cells and Lacking Tyrosinase Inhibitory Activity as New Leads in the Treatment of Leukemia
Mini-Reviews in Medicinal Chemistry Role of Oxidative and Nitrosative Stress, Longevity Genes and Poly(ADPribose) Polymerase in Cardiovascular Dysfunction Associated with Aging
Current Vascular Pharmacology Editorial (Thematic Issue: Progresses on Developing Nanomaterials for Cancer Diagnosis and Therapy)
Recent Patents on Nanomedicine High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters Current Approaches to Glycoprotein Analysis
Protein & Peptide Letters Current Status and Future Directions of Multimodality Therapy for Non- Small Cell Lung Cancer of the Superior Sulcus
Current Cancer Therapy Reviews Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets